导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.45% | 3392/4773 |
| 近一周 | -0.96% | 301/5461 |
| 近一月 | 2.62% | 250/5420 |
| 近一季 | 3.57% | 354/5208 |
| 近半年 | 0.52% | 1146/4919 |
| 近一年 | -4.29% | 3100/4366 |
| 近两年 | 35.55% | 2072/2954 |
| 近三年 | 27.15% | 1176/2253 |
| 成立以来 | 139.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.13% 4352/4961 |
-4.49% 3515/5312 |
- - |
- - |
| 2025 | 10.36% 2817/4813 |
-1.70% 2753/3635 |
8.68% 320/4076 |
-0.42% 3925/4524 |
3.74% 636/4813 |
| 2024 | 34.18% 63/3463 |
2.95% 654/2808 |
0.93% 525/3014 |
26.71% 251/3129 |
1.92% 1006/3463 |
| 2023 | -4.86% 698/2656 |
-0.90% 1834/2280 |
0.13% 339/2385 |
5.00% 105/2515 |
-8.69% 2304/2655 |
| 2022 | -11.87% 262/2207 |
-5.23% 182/1919 |
-1.27% 1697/2016 |
-10.60% 431/2113 |
5.35% 471/2208 |
| 2021 | -7.89% 1042/1822 |
-1.34% 471/1255 |
-2.55% 1213/1330 |
-4.83% 738/1466 |
0.66% 1083/1822 |
| 2020 | 5.91% 878/1250 |
-14.87% 972/1028 |
4.68% 903/1067 |
11.74% 429/1164 |
6.36% 760/1184 |
| 2019 | 34.95% 388/1092 |
28.75% 295/754 |
0.65% 164/804 |
-2.71% 712/850 |
7.04% 495/918 |
| 2018 | -19.46% 166/834 |
- - |
- - |
- - |
-9.43% 144/691 |
| 2017 | 17.41% 227/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.96% 253/605 |
- - |
- - |
- - |
- - |
| 2015 | -2.27% 264/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 嘉实中证金融地产ETF VS. 长安沪深300非周期A(740101) |